Advanced Biomedical Technologies Inc. (ABMT) financial statements (2022 and earlier)

Company profile

Business Address 200 PARK AVENUE, SUITE 1700
NEW YORK, NY 10166
State of Incorp.
Fiscal Year End October 31
SIC 3842 - Orthopedic, Prosthetic, and Surgical Appliances and Supplies (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in thousands)

7/31/2021
Q3
4/30/2021
Q2
1/31/2021
Q1
10/31/2020
Q4
7/31/2020
Q3
4/30/2020
Q2
1/31/2020
Q1
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments76820214118
Cash and cash equivalents76820214118
Inventory, net of allowances, customer advances and progress billings189159122100806549
Inventory189159122100806549
Other undisclosed current assets47535629353660
Total current assets:243218187331130112117
Noncurrent Assets
Operating lease, right-of-use asset10132233425265
Property, plant and equipment14414712210511011296
Total noncurrent assets:154161145138152165160
TOTAL ASSETS:397379332469282276278
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:1,160      
Other undisclosed accounts payable and accrued liabilities1,160      
Due to related parties5,4345,3515,2494,7065,0835,1195,045
Other undisclosed current liabilities1,9852,9972,9123,1582,1811,8641,852
Total current liabilities:8,5798,3488,1617,8647,2656,9836,897
Noncurrent Liabilities
Long-term debt and lease obligation  47101322
Operating lease, liability  47101322
Total noncurrent liabilities:  77202645
Total liabilities:8,5798,3488,1687,8787,2857,0096,942
Stockholders' equity
Stockholders' equity attributable to parent, including:(8,182)(7,969)(7,833)(7,402)(6,993)(6,720)(6,642)
Common stock1111111
Additional paid in capital2,8362,8322,8282,8242,7832,7792,772
Accumulated other comprehensive income (loss)(211)(197)(246)21280356234
Accumulated deficit(10,816)(10,617)(10,428)(10,256)(10,063)(9,858)(9,648)
Other undisclosed stockholders' equity attributable to parent91313872 
Total stockholders' equity:(8,182)(7,969)(7,833)(7,402)(6,993)(6,720)(6,642)
Other undisclosed liabilities and equity  (4)(7)(10)(13)(22)
TOTAL LIABILITIES AND EQUITY:397379332469282276278

Income statement (P&L) ($ in thousands)

7/31/2021
Q3
4/30/2021
Q2
1/31/2021
Q1
10/31/2020
Q4
7/31/2020
Q3
4/30/2020
Q2
1/31/2020
Q1
Revenues0047621 61
Revenue from related parties  47    
Cost of revenue  (10)   (33)
Other undisclosed gross profit(0)(0) (18)(1)(0) 
Gross profit:0037440(0)27
Operating expenses(112)(113)(126)(155)(117)(120)(127)
Operating loss:(112)(113)(89)(110)(116)(120)(100)
Nonoperating income (expense)(87)(76)(83)(83)(89)(89)36
Interest and debt expense(1)(0)(73)(3)(3)(3)(3)
Loss from continuing operations before equity method investments, income taxes:(199)(189)(245)(197)(209)(213)(67)
Other undisclosed income from continuing operations before income taxes10733333
Net loss available to common stockholders, diluted:(199)(189)(172)(193)(205)(210)(64)

Comprehensive Income ($ in thousands)

7/31/2021
Q3
4/30/2021
Q2
1/31/2021
Q1
10/31/2020
Q4
7/31/2020
Q3
4/30/2020
Q2
1/31/2020
Q1
Net loss:(199)(189)(172)(193)(205)(210)(64)
Other comprehensive income (loss)(15)49(267)(259)(76)122(100)
Comprehensive loss, net of tax, attributable to parent:(214)(140)(439)(452)(281)(88)(164)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: